|
Volumn 23, Issue 1, 2013, Pages 3-5
|
Smoothing Out Drug Resistance
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ARSENIC TRIOXIDE;
BMS 833923;
CYCLIN D1;
CYTOCHROME P450;
IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;
ITRACONAZOLE;
LY 2940680;
MAMMALIAN TARGET OF RAPAMYCIN;
MULTIDRUG RESISTANCE PROTEIN;
NOTCH RECEPTOR;
NVP LED225;
PHOSPHATIDYLINOSITOL 3 KINASE;
PROMYELOCYTIC LEUKEMIA PROTEIN;
PROTEIN PATCHED 1;
RETINOIC ACID;
S6 KINASE;
SARIDEGIB;
SMOOTHENED PROTEIN;
SONIC HEDGEHOG PROTEIN;
SONIDEGIB;
TRANSCRIPTION FACTOR GLI2;
UNCLASSIFIED DRUG;
VASCULOTROPIN RECEPTOR 2;
VISMODEGIB;
WNT PROTEIN;
ADVANCED CANCER;
BASAL CELL CARCINOMA;
CANCER STAGING;
CANCER SURVIVAL;
CELL DIFFERENTIATION;
CELL GROWTH;
CELL MEMBRANE;
CELL PROLIFERATION;
DRUG EFFICACY;
ENZYME ACTIVATION;
GENE AMPLIFICATION;
GENE MUTATION;
GENE OVEREXPRESSION;
HUMAN;
MEDULLOBLASTOMA;
MOLECULARLY TARGETED THERAPY;
NONHUMAN;
PHASE 2 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
RNA INTERFERENCE;
SHORT SURVEY;
SIGNAL TRANSDUCTION;
SKIN CARCINOMA;
TREATMENT RESPONSE;
TUMOR GROWTH;
TUMOR VOLUME;
ERINACEIDAE;
|
EID: 84872369752
PISSN: 15356108
EISSN: 18783686
Source Type: Journal
DOI: 10.1016/j.ccr.2012.12.011 Document Type: Short Survey |
Times cited : (11)
|
References (10)
|